Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Erlotinib, and 5-FU with Radiation for Rectal Cancer
NCT00307736Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- May 2006
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in rectal cancer, sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose of Erlotinib at 3 years. Started May 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00307736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307736.